Patents Assigned to ARAVAX PTY LTD
  • Publication number: 20240415955
    Abstract: The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof.
    Type: Application
    Filed: April 22, 2024
    Publication date: December 19, 2024
    Applicant: ARAVAX PTY LTD.
    Inventors: Robyn Elizabeth O'Hehir, Sara Rachel Prickett, Jennifer May Rolland
  • Publication number: 20240350599
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
    Type: Application
    Filed: March 26, 2024
    Publication date: October 24, 2024
    Applicant: ARAVAX PTY LTD
    Inventors: ROBYN O'HEHIR, JENNIFER ROLLAND, SARA PRICKETT
  • Publication number: 20240350600
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
    Type: Application
    Filed: June 26, 2024
    Publication date: October 24, 2024
    Applicant: ARAVAX PTY LTD
    Inventors: ROBYN O'HEHIR, JENNIFER ROLLAND, SARA PRICKETT
  • Publication number: 20240252607
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara H 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
    Type: Application
    Filed: December 22, 2023
    Publication date: August 1, 2024
    Applicant: ARAVAX PTY LTD
    Inventors: ROBYN O'HEHIR, JENNIFER ROLLAND, SARA PRICKETT
  • Patent number: 11980658
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: May 14, 2024
    Assignee: ARAVAX PTY LTD
    Inventors: Robyn O'Hehir, Jennifer Rolland, Sara Prickett
  • Patent number: 11266737
    Abstract: The present invention relates generally to an immunotherapeutic composition. More particularly, the present invention relates to an immunotherapeutic composition which interacts immunologically with T lymphocytes in subjects having peanut allergy or allergy to other tree nuts. This composition is preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 and/or Ara h 2 allergens. The composition of the present invention is useful in the therapeutic or prophylactic treatment of conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to peanut, Ara h 1 and/or Ara h 2 or derivative or homologue thereof.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: March 8, 2022
    Assignee: ARAVAX PTY LTD
    Inventors: Robyn Elizabeth O'Hehir, Sara Rachel Prickett, Jennifer May Rolland
  • Patent number: 11096994
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferably immunointeractive with T cells in subjects having an allergy to the Ara h 1 allergen. The molecules of the present invention are useful in the development of diagnostic, therapeutic and prophylactic agents for conditions characterised by an aberrant, inappropriate or otherwise unwanted immune response to Ara h 1 or derivative or homologue thereof.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: August 24, 2021
    Assignee: ARAVAX PTY LTD
    Inventors: Robyn O'Hehir, Jennifer Rolland, Sara Prickett